EGFR and lung cancer: Another similar study showed that the ORR following first-line treatment with icotinib was 52.6% (95% CI = 43.1–61.9%) for 116 patients with advanced lung cancer of unknown pathological status who had EGFR-sensitizing mutations in their ctDNA.